Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress Entering 2023 with strong momentum and a robust pipeline of proprietary, first-in-class compoundsFirst...

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer OATD-02 is an oral, potent and selective dual arginase...